Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy 1.7mg dose is the fourth step on the licensed semaglutide titration schedule, sitting between the 1mg dose and the 2.4mg maintenance level. Most people reach it around week 13 of treatment after moving through 0.25mg, 0.5mg and 1mg in roughly four-week stages. It is a prescription-only medicine, so your prescriber decides when (and whether) you move to this dose based on how your body has responded so far. If you've been counting down to 1.7mg and wondering what it changes, this page covers exactly that.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy's titration schedule exists for a specific reason: starting at a lower dose and moving up gradually gives your digestive system time to adapt. The sequence runs 0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg, with roughly four weeks at each level. You can read the full breakdown on our Wegovy dose guide if you want the complete picture.
1.7mg is the last step before maintenance. That framing matters. Some people feel the most noticeable side-effect activity around this stage, appetite suppression becomes stronger, and GI effects can resurface briefly after the increase. That's normal, and for most people it settles within a week or two. If you're anxious about moving up and wondering whether the process is working as it should, that's an entirely reasonable thing to feel. Our prescribers hear it most weeks.
The licensed schedule is described in the Wegovy Summary of Product Characteristics, published on the Electronic Medicines Compendium, which is the authoritative source for exact timing and dose detail. Your prescriber will have reviewed this before confirming your increase.
Each Wegovy pre-filled pen is designed to deliver the full dose in a single injection. The audible click (sometimes accompanied by a visible window change) is the pen's built-in confirmation that the injection mechanism completed correctly. It doesn't mean the dose was absorbed, but it does mean the pen fired as intended.
Technique affects this. The pen should be held firmly against the skin with a little pressure for the full duration recommended in the Patient Information Leaflet, even after you hear the click. Lifting it too early risks an incomplete injection. Rotating injection sites (abdomen, thigh and upper arm are all licensed options) helps reduce local skin reactions over time. If you want a detailed look at what each click count means at this specific dose setting, our Wegovy clicks 1.7 guide covers the specifics, and you can also use our Wegovy 1.7 click chart as a quick visual reference alongside our click-to-dose reference for all settings.
If you didn't hear or feel a click, or the window didn't change as expected, don't give a second dose. Contact your prescriber or pharmacist for guidance, the right answer depends on individual circumstances and the Patient Information Leaflet, not a general rule.
Nausea, constipation, diarrhoea, indigestion and fatigue are the most commonly reported effects when moving to a higher Wegovy dose. They tend to be most noticeable in the first few days after an increase and improve as the body adjusts. Staying well hydrated and eating smaller, lower-fat meals can reduce GI discomfort during the transition.
One side effect that always warrants prompt medical attention is severe stomach pain that radiates toward the back, with or without vomiting. In January 2026 the MHRA issued a Drug Safety Update reminding prescribers and patients that acute pancreatitis is a known, infrequent but serious risk with GLP-1 medicines; if you experience that specific pain pattern, seek urgent help rather than waiting it out. You can also report any suspected side effect through the Yellow Card scheme.
The NHS semaglutide medicines page lists the full side-effect profile with plain-language descriptions of what's common, uncommon and rare, it's worth a read before your dose increase if you want to know what to watch for.
Reaching 1.7mg doesn't automatically mean 2.4mg follows in four weeks. Your prescriber will look at how you've responded: tolerance, any ongoing side effects and whether weight loss is progressing as expected. For some people, 1.7mg becomes the effective long-term dose if 2.4mg isn't tolerated. That's a clinical decision, not a setback.
It's also worth knowing that the cost of treatment can change at different doses, since pricing reflects the pen strength dispensed. Our Wegovy price comparison page walks through how private prescription costs are structured in the UK, including what a transparent, all-in price should cover. At nume, the consultation, prescription and next-working-day delivery are all included, no separate fees per item.
If you'd like to understand the 2.4mg step before you reach it, the 2.4mg click guide covers what that dose change involves. And if you want to check whether you're eligible for treatment through a regulated private pharmacy, you can check your eligibility with our prescribers at any point, the consultation is free and reviewed the same day by a GPhC-registered clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.